SecBot SecBot

EVGN

Evogene Ltd.
Nasdaq· Agricultural Chemicals· Inc. L3· CIK 0001574565 Materials & Mining
$0.3700 +0.01 (+2.78%)
Oct 26 4:00 PM ET · prev $0.3600
Market cap
$5.9M
Nano cap
Median target
$2.15
+481% · range $2.15–2.15
Next earnings
Nov 18
in 22 days · EPS est. −$0.19
1 year
−70.9%
from $1.27 · Oct 27
30 days
−2.6%
from $0.3800
52-week range
$0.3600–1.31
−72% from high · low Oct 23
Avg volume 20D
3.67M
Sep 29 spike 60.32M
Short interest
🔒 Subscribers only
Insider net
+$692.1K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 2 bearish · 2 bullish · 2 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 6/9 ·Next Earnings date, Nov 18, 2026
Strongest BULLISH Activist investors L.I.A. Pure Capital and Invest-Pro have entered into a cooperation agreement with…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $692.1K at an average $0.5493. No open-market sales. Price is 33% below their cost.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 2 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.270 → −$0.190 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    20% below its 50-day average. New closing low $0.3600 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGADD10,790$4.7K
BNP PARIBAS FINANCIAL MARKETSTRIM2,830$1.2K
MORGAN STANLEYTRIM1,285$564.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +481%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
May 22, 2025Lake Street
MAINTAIN
MAINTAINBuy
Aug 23, 2024Lake Street
MAINTAIN
MAINTAINBuy
Oct 2, 2023Alliance Global Partners
INITIATE
INITIATEBuy
Aug 18, 2023Lake Street
MAINTAIN
MAINTAINBuy
Jul 21, 2023Roth MKM
MAINTAIN
MAINTAINBuy
May 2, 2023Lake Street
INITIATE
INITIATEBuy

Insider ledger

Form 4
$692.1K
bought · 1 insider
$0
sold · 0 insiders
−32.6%
vs their $0.5493 cost
DateInsiderTypeValue
Sep 4, 2026
Nimrodi Nir
Director
AWARD10,000 sh
Sep 4, 2026
Percy Adrian John
Director
AWARD2,500 sh
Sep 4, 2026
Falk Dan Michael
Director
AWARD2,500 sh
Sep 4, 2026
RECANATI LEON
Director
AWARD2,500 sh
Aug 11, 2026
RECANATI LEON
Director
BUY$292.1K
Aug 4, 2026
RECANATI LEON
Director
BUY$400.0K

Earnings setup

Estimates
Nov 18
reports in 22 days
−$0.19
EPS estimate, this quarter
+30%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.19-$0.19–-$0.19+29.6%$365.0K
Next Q-$0.20-$0.20–-$0.20+25.9%$390.0K
Current FY-$1.10-$1.10–-$1.10+35.3%$1.4M
Next FY-$0.60-$0.60–-$0.60+25.0%$2.6M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Two Form 3 filings were filed on 2026-10-22, reporting Oz Adler and Adi Zuloff-Shani as new beneficial owners of…
3 — Impact 2/10
Oct 6, 2026 SEC
Activist investors L.I.A. Pure Capital and Invest-Pro have entered into a cooperation agreement with Evogene…
SC 13D/A — Impact 6/10
Oct 6, 2026 SEC
Evogene entered into a cooperation agreement with activist shareholders L.I.A. Pure Capital and Invest-Pro, resolving…
6-K — Impact 6/10
Sep 30, 2026 Other
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) (the "Compa
Sep 4, 2026 Insider
Nimrodi Nir was granted 10,000 shares
Director
Sep 4, 2026 Insider
Percy Adrian John was granted 2,500 shares
Director
Sep 4, 2026 Insider
Falk Dan Michael was granted 2,500 shares
Director
Jun 30, 2026 Inst.
UBS Group AG — ADD
10,790 shares ($4.7K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
EVGN Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Sep 30, 2026
Press release
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a pioneer in computational…
Aug 31, 2026
Press release
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
Company urges shareholders to evaluate the significant changes already implemented and vote FOR all Evogene nominees on September 4, 2026, Annual…
Aug 18, 2026
Earnings date
EVGN Q2 2026 Earnings Scheduled — 2026-08-18
Aug 14, 2026
Earnings
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
Zoom conference call scheduled for August 18, 2026, at 9:00 AM ET REHOVOT, Israel, Aug. 14, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE…
Jul 8, 2026
Press release
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
Supporting Israel's Academic Innovation Ecosystem: BCDD to Provide World-Class Experimental Infrastructure, Evogene to Deliver Computational…

SecBot reports

16 filings · 2 bullish · 6 bearish · 2 mixed · 6 neutral
All EVGN filing & press-release reports (16)